

Program Announcement

WALTER REED ARMY INSTITUTE OF RESEARCH (WRAIR)

**Fiscal Year (FY) 12 Medical Tropical Research Laboratory Program (MTRLP)
Infectious Disease Research Award (IDRA)**

**Funding Opportunity Number: W81XWH-12-WRAIR-MTRLP-IDRA
Catalog of Federal Domestic Assistance Number: 12.420**

SUBMISSION AND REVIEW DATES AND TIMES

Invitation to Submit an Application: September 9, 2011

Application Submission Deadline: 11:59 p.m. ET, October 31, 2011

Scientific Peer Review: November 2011

Programmatic Review: December 2011

New for FY11: The Grants.gov Research & Related Budget form is a mandatory component of all Grants.gov application packages.

TABLE OF CONTENTS

I. Funding Opportunity Description	3
A. Program Description	3
B. Award Information.....	3
C. Eligibility Information	6
D. Funding	6
II. Submission Information	7
A. Where to Obtain the Application Package.....	7
To obtain the complete application package, including all required forms, perform a Grants.gov (http://www.grants.gov/) basic search using the Funding Opportunity Number: W81XWH-12-WRAIR-MTRLP-IDRA.	7
B. Application Submission Content and Form.....	7
The Authorized Organizational Representative (AOR) is responsible for ensuring that the total budget does not exceed the total cost allowed for this Program Announcement.	7
C. Submission Dates and Times	11
D. Other Submission Requirements.....	11
III. Application Review Information.....	11
A. Application Review and Selection Process.....	11
B. Application Review Criteria	12
C. Recipient Qualification	13
Refer to the General Application Instructions, Appendix 1, for additional information on organization and Government agency requirements.....	13
D. Application Review Dates	14
E. Notification of Application Review Results	14
IV. Administrative Actions	14
A. Rejection	14
B. Modification.....	14
C. Withdrawal.....	14
D. Withhold	15
V. Award Administration Information.....	15
A. Award Notice	15
Awards will be made no later than February 6, 2012. Refer to the General Application Instructions, Appendix 4, for additional award administration information.	15
B. Administrative and National Policy Requirements.....	15
C. Reporting.....	15
D. Award Transfers.....	15
E. Pre-Award Meeting.....	15
VI. Agency Contacts	16
Grants.gov Contact Center.....	16
Questions related to application submission through the Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. Federal holidays).....	16
VII. PI Application Submission Checklist	17

I. FUNDING OPPORTUNITY DESCRIPTION

A. Program Description

The United States Army Medical Component (USAMC) - Armed Forces Research Institute of Medical Sciences (AFRIMS) is a Special Foreign Activity of the Walter Reed Army Institute of Research (WRAIR) located in Bangkok, Thailand. The AFRIMS is one of the premier tropical medicine research laboratories in the world. The primary mission of AFRIMS is to develop new products to detect, prevent and control tropical infectious diseases, and to conduct surveillance of endemic and emerging infectious diseases. AFRIMS collaborates with researchers and public health officials in the government, military and private sectors to conduct high quality preclinical, clinical and epidemiological research to support this mission. AFRIMS objectives are to discover and explore innovative approaches to protect, support, and advance the health and welfare of the U.S. Military and at-risk populations in the region; to accelerate the transition of medical technologies into deployable products; to accelerate the translation of advances in knowledge into new medical products.

B. Award Information

This Program Announcement/Funding Opportunity, WRAIR Medical Tropical Research Laboratory Program (MTRLP) Infectious Disease Research Award (IDRA) is soliciting proposals that support the basic, pre-clinical and clinical research of infectious diseases within Thailand and the region of Southeast (SE) Asia in conjunction with the Royal Thai Army Medical Department and the AFRIMS. This opportunity will focus on research and operational support for the study of militarily relevant infectious diseases of interest to the United States Military and the Royal Thai Army (RTA). Activities include basic scientific research, disease surveillance, testing in animal models, and phase 1-3 clinical trials of biologics, drugs and devices intended for the detection and prevention of tropical infectious diseases.

Award under this announcement will consist solely of a Cooperative Agreement.

Research will be focused on infectious disease threats that are of US military medical importance. These studies must be responsive to the health care needs of military service members and, to the extent possible, civilian populations in tropical regions worldwide. A prioritization has most recently been determined by an expert panel convened by the US Army Medical Command Directorate of Combat and Doctrine Development, Ft. Sam Houston, TX, USA. (See attached memo entitled "Infectious disease threats to the US Military Prioritization Panel results", 23 April 2010.) The MTRLP-IDRA will support basic scientific research, surveillance, preclinical (including animal models) and clinical trials that meet local government regulations, US Military, RTA and US FDA standards. The research proposal will include surveillance of evolving and emerging infectious disease threats. The derived data will include seasonality and location so that it informs decisions about field site location and maintenance. The FY12 MTRLP-IDRA seeks applications focused on development of tools and methods to predict, detect, prevent and control arthropod-borne disease threats, diarrheal disease, hepatitis, HIV, influenza and related respiratory infections, and drug-resistant bacteria that cause delayed

wound healing (especially trauma associated). The purpose of such a range of research is to accelerate translation of medical concepts and discoveries to standardized and approved products.

This opportunity will provide funding for the research, personnel and facilities support required for the ongoing and continued scientific initiatives of the USAMC-AFRIMS over the 5 years of the Agreement. The application should demonstrate the ability to provide scientific, logistical and administrative personnel required to support AFRIMS research efforts, as well as secure adequate facilities for optimal conduct of the research.

The applicant's research proposal will be a 5-year plan for the testing and development of new products (drugs, diagnostics and vaccines) that prevent or treat infectious disease threats to the deployed military member. It will further increase understanding of how these agents cause morbidity and mortality, by studying semi-immune and non-immune populations in endemic areas when that is relevant to the disease outcome.

The application should demonstrate the ability to continue and facilitate the scientific and medical research objectives of the WRAIR and USAMC-AFRIMS during FY12-16. In general, the application should demonstrate the ability to:

Provide technical and scientific research support;

Provide operational and logistics support required to achieve research objectives;

Provide administrative and financial reporting support;

Provide office, laboratory and animal facilities, and associated security;

Provide expertise in host nation labor law and personnel management;

Provide liaison support to local public health authorities and academic institutions.

Applications must address all of the following research focus areas:

- 1.** Multi-drug resistant malaria, surveillance and parasite mechanisms; safe and effective malaria prevention drugs; safe and effective preventive vaccines for falciparum and/or vivax malaria.
- 2.** Surveillance, characterization, and development of diagnostics and vaccines for viruses of military importance, to include the following: dengue fever, influenza, Japanese encephalitis, hepatitis, and chikungunya.
- 3.** Surveillance and characterization of diarrhea etiology and antimicrobial resistance; development of diagnostics for enteric pathogens, including shigella, enterotoxigenic *E.coli* (ETEC), campylobacter, cryptosporidia and norovirus; a safe and effective preventive vaccine for shigella.

4. A safe and effective preventive vaccine for HIV infection; pathophysiology of acute HIV infection and molecular diagnostics for viral variation.
5. Detection and identification of bacterial pathogens of importance throughout the chain of evacuation from field to tertiary hospital, specifically *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, extended-spectrum beta-lactamase producers, *Klebsiella*, and methicillin-resistant *Staphylococcus aureus*, and invasive, non-*Candida* fungal pathogens.
6. Determination of optimal prophylaxis and therapy for infections of trauma-induced wounds. Priority pathogens are listed in #5 above; related biofilms are also an important research focus.
7. Development and evaluation of conventional and rapid field molecular assays for the detection of emerging/re-emerging pathogens and/or their vectors.
8. Animal models to support product development, with special focus on drugs for prevention of falciparum malaria and vaccines for prevention of dengue, shigella and scrub typhus. Associated with these models is the maintenance of an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited animal use program with a non-human primate and mouse breeding colonies.
9. Surveillance of emerging and re-emerging infectious diseases and their drug sensitivities in Thailand and the SE Asia region.

The following are important aspects of submission for the MTRLP-IDRA:

- The proposal must describe a research plan for a 5-year period, which includes laboratory, animal and human studies. The proposed research projects should be based on sound scientific rationale that is established through logical reasoning, critical review and analysis of the literature as documented in the application and, if available, prevalence or incidence of the pathogen or disease of interest in Thailand or Southeast Asia.
- The proposal must describe the personnel expertise which would be provided for the conduct and support of the research. The proposal must demonstrate institutional support and expert knowledge of host country labor laws.
- The applicant must provide adequate building space to support the AFRIMS research mission and administrative support for this project. Required space is estimated as: i) 6000 sq meters for research laboratories and associated offices, ii) 4000 sq meters to house a vivarium and insectary, and all organic technical personnel required to maintain the respective facility, as well as provide managerial oversight for the specialized facilities, and iii) 3500 sq meters for core administrative support. Physical security must also be provided at all locations.
- The proposal must describe the planned financial management, with special focus on staff salaries and utility charges.

- The applicant must demonstrate capability to act as sponsor and liaison for the USAMC-AFRIMS to the local public health authorities, especially as it pertains to applicable laws and regulations of the Kingdom of Thailand.

Research Involving Human Subjects:

All USAMC-AFRIMS research involving human subjects and human tissues must be reviewed and approved by the Institutional Review Board (IRB) of the Walter Reed Army Institute of Research in addition to the local IRB of record. The WRAIR IRB is mandated to comply with specific laws and directives governing all research involving human subjects that is supported by the DOD. Selected studies must also be approved by the USAMRMC Office of Research Protections' Human Research Protections Office prior to implementation. These laws and directives are rigorous and detailed, and will require information in addition to that supplied to the local IRB. Allow a minimum of four (4) months for regulatory review and approval processes. Refer to Appendix 5 of the General Application Instructions for more information. The term "human subjects" is used in this Program Announcement/Funding Opportunity to refer to individuals who will be recruited for, or who will participate in, the proposed clinical trial.

Research Involving Animal Use:

Specific documents relating to the use of animals in any proposed research will be submitted and approved by the local Institutional Animal Care and Use Committee prior to commencement of any resultant protocol. The Animal Care and Use Review Office (ACURO), a component of the USAMRMC Office of Research Protections, must also review and approve all animal use prior to the start of working with animals. Allow two (2) to four (4) months for regulatory review and approval processes for animal studies. Refer to Appendix 5 of the General Application Instructions, for more information. Contact ACURO for additional information via the central email box, ACURO@amedd.army.mil.

C. Eligibility Information

- This Program Announcement/Funding Opportunity is intended only for extramural investigators.
- Independent investigators at any academic level (or equivalent) are eligible to submit applications.
- Cost sharing/matching is not an eligibility requirement.
- Refer to the Appendix 1 of General Application Instructions for general eligibility information.

D. Funding

- The maximum period of performance is **5** years.
- The maximum allowable total costs for the entire period of performance are **\$42,700,000** including indirect costs.

- Regardless of the period of performance proposed, the applicant may not exceed the maximum allowable total costs. Indirect costs shall be proposed in accordance with the organization's negotiated rate agreement

Refer to Section II.B., of the General Application Instructions, for budget regulations and instructions for the Research and Related Budget form. In addition, for this award mechanism, direct costs may be requested for (not all-inclusive):

- Salaries, including salary for a Study Coordinator
- Research-related subject costs
- Utilities
- Clinical research costs
- Support for multidisciplinary collaborations
- Travel between collaborating organizations

The WRAIR expects to fund one FY 12 MTRLP-IDRA application, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of Federal funds for this Program. Funding allotted for this Program Announcement/Funding Opportunity is approximate and subject to realignment.

II. SUBMISSION INFORMATION

Applications shall be submitted through Grants.gov (<http://www.grants.gov/>).

Submission of the same research project to different funding opportunities within the same program and fiscal year is discouraged. The Government reserves the right to reject duplicative applications.

A. Where to Obtain the Application Package

To obtain the complete application package, including all required forms, perform a Grants.gov (<http://www.grants.gov/>) basic search using the Funding Opportunity Number: W81XWH-12-WRAIR-MTRLP-IDRA.

B. Application Submission Content and Form

The Authorized Organizational Representative (AOR) is responsible for ensuring that the total budget does not exceed the total cost allowed for this Program Announcement.

Each application submission must include the completed application package of forms and attachments provided in Grants.gov for this Program Announcement/Funding Opportunity. The application package is submitted by the Authorized Organizational Representative (AOR) through the Grants.gov portal (<http://www.grants.gov/>).

Grants.gov application package components: For the MTRLP-IDRA Award, the Grants.gov application package includes the following components (refer to the General Application Instructions, Section II.B., for additional information on application submission):

1. **SF 424 Research & Related (R&R) Application for Federal Assistance Form:**
Refer to Section II.B., of the General Application Instructions, for detailed information.
2. **Attachments Form**

Note: All essential elements of the proposal must be included as directed in Attachment 1 (the Project Narrative) and Attachments 2-6 described below. Failure to submit these attachments as part of the application package will result in rejection of the entire application.

- **Attachment 1: Project Narrative (20-page limit):** Upload as “ProjectNarrative.pdf.”

Describe the proposed project in detail using the outline below.

- **Research Objectives:** Describe in detail the plan for how each of the research focus areas listed in Section I.B. above will be addressed over the 5-year period of the Agreement. This should include a rationale for what is being studied and how steps will build on each other over time. The plan should consider the full range of surveillance, preclinical *in vitro* and animal studies, and human clinical studies of phase 1 thru 4. (Phase 4 post-licensure studies are unlikely but could be applicable in the AFRIMS setting.) A background section should make clear the importance of the particular endemic disease and what important gaps remain in terms of its diagnosis, prevention and/or treatment. The need for surveillance and control measures is also to be considered fully. This section should establish the relevance of the specific research proposed and explain the applicability of the potential findings.
- **Personnel to Accomplish Objectives:** Provide a description of the personnel proposed to carry out the research agenda, noting how this may vary over the 5-year period of the Agreement. Describe experience and expertise in complying with Thai labor laws, and how this would be built into plan for personnel management.
- **Facilities and equipment:** Describe the facilities which would be provided to carry out the research objectives, bearing in mind the requirements stated in Section I.B, page 5 above. Maintenance of AAALAC accreditation of animal facility is a priority, as is maintenance of level 3 biosafety laboratories (compliant with DoD biosurety regulations) for both *in vitro* and animal studies. Any particularly relevant infrastructure to be provided, or to be put in place during the 5-year period of the Agreement should be described. Physical security must be provided and these measures should be described.
- **Funding of Research:** It is expected that both DoD and non-DoD funds will need to be obtained during the 5-year period of the Agreement to carry out the

proposed research. Describe the sources from which these funds will be sought and how this will be done. If costs are projected to increase or decrease for specific research projects over the 5-year period of the Agreement, this should be described in the Narrative and taken into account in the budget projections.

- **Strategic Communications:** Describe how the applicant will function as liaison between the USAMC-AFRIMS and the various Ministries of the Kingdom of Thailand, specifically with the Ministry of Public Health and the Royal Thai Army Medical Department. Describe how the Institute's mission will be communicated to its various stakeholders and partners, to include DoD, other United States Government agencies (NIH and Dept of State), Non-Governmental Organizations, host country authorities and population.
- **Attachment 2: Supporting Documentation.** Start each document on a new page. Combine and upload as a single file named "Support.pdf." If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. *Each component has no page limit unless otherwise noted.*
 - References Cited: List the references cited (including URLs if available) in the project narrative using a standard reference format that includes the full citation (i.e. author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).
 - List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.
 - Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project, and any additional facilities or equipment proposed for acquisition at no cost to the USAMRMC. Indicate if Government-owned facilities or equipment are proposed for use. Reference should be made to the original or present contract under which the facilities or equipment items are now accountable. There is no form for this information.
 - Publications and/or Patent Abstracts (five-document limit): Include relevant publication URLs and/or patent abstracts. If publications are not publicly available, then they must be included. Extra items will not be reviewed.
 - Letters of Organizational Support (two-page limit per letter): Provide a letter (or letters if applicable), signed by the appropriate organization official, reflecting the facility space, equipment, and other resources available for the project.
 - Letters of Collaboration (if applicable) (two-page limit per letter): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work.
 - Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations. Disclose any patents, issued or pending, and/or licenses, granted and/or pending, with respect to the intervention. Discuss and document availability of and access to the intervention. Provide documentation of access

to and permission to use all intellectual and material property, as applicable.

- Data and Research Resources Sharing Plan: Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to Appendix 4, of the General Application Instructions, for more information about expectations for making data and research resources publically available.

- **Attachment 3: Technical Abstract (one-page limit):** Upload as “TechAbs.pdf.”

Technical abstracts should be written using the outline below. (Proprietary or confidential information should *not* be included.)

- Research Objectives: State the objectives of the research being proposed.
- Personnel Plan: Describe the plan for how the research project will be staffed and how these staff will be managed, optimally and in accordance with Thai law.
- Facilities and Equipment: Describe the facilities and equipment to be provided in support of the proposed research.
- Funding: Describe where and how funds will be sought to support the proposed research.
- Strategic Communications: Describe how the AFRIMS research mission will be communicated to key stakeholders and partners.
- Military Relevance: Describe the relevance of the proposed research to the U.S. Military.

- **Attachment 4: Public Abstract (one-page limit):** Upload as “PublicAbs.pdf.”

Public abstracts should be written using the outline below.

- Clearly describe, in a manner readily understood by lay persons, the rationale and objectives for the proposed research.
 - Do not duplicate the technical abstract.
- Describe the ultimate applicability of the research.
 - How will it strengthen the U.S. Military's capacity to function in tropical environments?
 - What are the potential medical applications, benefits, and risks to the general populations of the tropics?

- **Attachment 5: Statement of Work (SOW) (three-page limit):** Upload as “SOW.pdf.” see Section II.C. of the General Application Instructions, for detailed information.

- **Attachment 6: Military Relevance Statement (one-page limit):** Upload as “MilRel.pdf.”

Describe how the proposed research is responsive to need for improved diagnostics, preventives and treatments of tropical infectious diseases which are assessed to be threats to the U.S. Military. Provide information about the incidence and/or

prevalence of the disease or condition in military service members and/or veterans, if appropriate and available.

If active duty military and/or veteran population(s) will be used in the proposed research projects, describe the population(s), the appropriateness of the population(s) for the proposed study, and the feasibility of accessing the population. If non-military populations will be used for the proposed research projects, explain how the populations simulate the targeted population (i.e., military service members or veterans).

C. Submission Dates and Times

All submission dates and times are indicated on the [title page](#) of this Program Announcement/Funding Opportunity. Application submissions are required.

D. Other Submission Requirements

Refer to Appendix 2, of the General Application Instructions, for detailed formatting guidelines.

All applications must be submitted through Grants.gov. Organizations are required to provide a Data Universal Number System (DUNS) number and register with the Central Contractor Registry (CCR) to submit applications through the Grants.gov portal. Refer to Appendix 3, of the General Application Instructions, for information on Grants.gov requirements.

III. APPLICATION REVIEW INFORMATION

A. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumer advocates using a two-tier review process. The first tier is a peer review of applications against established criteria for determining technical merit. The second tier is a programmatic review that compares applications to each other and makes recommendations for funding to the Director, Overseas Laboratories for concurrence, and then to the Commanding General for final approval, based on technical merit, the relevance to the mission of the DOD and WRAIR, and the specific intent of the award mechanism. The highest scoring applications from the first tier of review are not automatically recommended for funding.

All WRAIR review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Each level of review requires panelists to sign a non-disclosure statement attesting that application and evaluation information will not be disclosed outside the panel. Violations of the non-disclosure statement can result in the dissolving of a panel(s) and other corrective actions. Organizational personnel and PIs are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization's application. Violations by panelists or PIs that compromise the confidentiality of the review process may also result in suspension or debarment of their employing organizations from Federal awards. Furthermore, it is a crime for Federal officials to

disclose confidential information of one party to another third party (Title 18 United States Code 1905).

B. Application Review Criteria

- 1. Peer Review:** To determine technical merit, all applications will be evaluated according to the following scored criteria, which are listed in descending order of importance:

- **Research Strategy and Infectious Disease Research Impact**

1. How the results of the proposed infectious disease research will advance surveillance, characterization, and development of diagnostics, drugs and vaccines for infectious diseases of military import (as assessed by an expert panel convened by the US Army Medical Command Directorate of Combat and Doctrine Development, Ft. Sam Houston, TX; memo entitled "Infectious disease threats to the US Military -- Prioritization Panel results", 23 April 2010). (Atch 1)
2. How well the infectious disease research aims, hypotheses or objectives, experimental design, and methods are designed to clearly answer the research objectives.

- **Support Considerations**

1. Demonstrate capability to act as sponsor and liaison for the USAMC-AFRIMS to the Government of Thailand and the Royal Thai Army (RTA) Medical Department especially as it pertains to applicable labor and intellectual property laws and research regulations of the Kingdom of Thailand.
2. How well the applicant demonstrates the ability to provide adequate building space to support the infectious disease research mission and administrative support for this project; required space is estimated at 1) 6000 sq meters for laboratory/research, 2) 4000 sq meters to house a vivarium, and 3) 3500 sq meters for administrative support.
3. How the proposal demonstrates the ability to support the development and continuation of animal models to support product development in militarily important infectious diseases (especially malaria) and the ability to sustain a high quality animal use program with AAALAC accreditation.

- **Personnel**

1. Whether the size and composition of the infectious disease research support team is appropriate.

2. To what degree the logistical team of the proposed infectious disease research (e.g., supply chain management, facility/medical maintenance, transportation operations) are adequate.

- **Budget**

Whether the budget is appropriate for the proposed research and support, and is within the limitations of this Program Announcement/Funding Opportunity.

- **Environment**

1. To what degree the research laboratories, the vivarium and clinical centers are accessible and conducive to collaborative research.
2. To what degree physical security is provided for the facilities and the U.S. Government assets and personnel within.
3. To what degree the applicant demonstrates institutional commitment to accomplish the proposed infectious disease research.
4. To what degree does applicant demonstrate capacity to support level 3 biosafety laboratories and expertise in U.S. DoD biosurety regulations.

- **Transition Plan**

To what degree the applicant demonstrates the ability to provide continuity with ongoing research.

In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

- **Application Presentation**

To what extent the writing, clarity, and presentation of the application components influenced the review.

2. **Programmatic Review:** To determine the application's relevance to the mission of the DOD and WRAIR, as well as to make funding recommendations, the following equally considered criteria are used by programmatic reviewers:

- Ratings and evaluations of the peer reviewers
- Military relevance
- Adherence to the intent of the award mechanism
- Responsiveness to all of the MTRLP-IDRA focus areas

C. Recipient Qualification

Refer to the General Application Instructions, Appendix 1, for additional information on organization and Government agency requirements.

D. Application Review Dates

All application review dates and times are indicated on the [title page](#) of this Program Announcement/Funding Opportunity.

E. Notification of Application Review Results

Each PI and organization will receive notification of the funding recommendation. PIs will receive a technical peer review summary statement on the strengths and weaknesses of the application.

IV. ADMINISTRATIVE ACTIONS

After receipt of applications from Grants.gov, the following administrative actions may occur:

A. Rejection

The following will result in administrative rejection of the application:

- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.

B. Modification

- Pages exceeding the specified limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.

C. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- FY12 MTRLP-IDRA member is found to be involved in the application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting document.
- Submission of the same research project to different funding opportunities within the same program and fiscal year.
- The application does not conform to this Program Announcement/Funding Opportunity description to an extent that precludes appropriate review.
- Direct costs as shown on the Research and Related Budget form exceed the maximum allowed by this Program Announcement/Funding Opportunity.
- Inclusion of URLs with the exception of links to published references.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- The PI does not meet the eligibility criteria.

D. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending institutional investigation. The institution will be required to provide the findings of the investigation to the US Army Medical Research Acquisition Activity (USAMRAA) Contracting/Grants Officer for a determination of the final disposition of the application.

V. AWARD ADMINISTRATION INFORMATION

A. Award Notice

Awards will be made no later than February 6, 2012. Refer to the General Application Instructions, Appendix 4, for additional award administration information.

B. Administrative and National Policy Requirements

Refer to the General Application Instructions, Appendix 4, Section C, for general information regarding administrative and national policy requirements.

C. Reporting

Refer to the General Application Instructions, Appendix 4, Section D, for general information on reporting requirements.

Quarterly technical progress reports will be required.

D. Award Transfers

Refer to the General Application Instructions, Appendix 4, Section E, for general information on organization or PI changes.

The transfer of an award to another institution is strongly discouraged. A transfer will not be allowed for any institution that includes a study site/clinical trial at its location. Approval of a transfer request from an institution that does not include a study site at its location will be at the discretion of the USAMRAA Contracting/Grants Officer.

E. Pre-Award Meeting

At the Government's discretion, the PI and Clinical Study Coordinator may be requested to participate in a pre-award meeting.

VI. AGENCY CONTACTS

Grants.gov Contact Center

Questions related to application submission through the Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. Federal holidays).

Phone: 1-800-518-4726

Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the Synopsis page for the Program Announcement/Funding Opportunity. If the application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

VII. PI APPLICATION SUBMISSION CHECKLIST

Grants.gov Application Components	Action	Completed
SF-424 (R&R) Application for Federal Assistance Form	Complete form as instructed.	
Attachments Form	Upload Project Narrative (ProjectNarrative.pdf) as Attachment 1.	
	Upload Supporting Documentation (Support.pdf) as Attachment 2.	
	Upload Technical Abstract (TechAbs.pdf) as Attachment 3.	
	Upload Public Abstract (PublicAbs.pdf) as Attachment 4.	
	Upload Statement of Work (SOW.pdf) as Attachment 5.	
	Upload Military Relevance Statement (MilRel.pdf) as Attachment 6.	
Research & Related Senior/Key Person Profile (Expanded)	Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.	
	Attach PI Current & Pending Support (Support_LastName.pdf) to the appropriate field.	
	Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.	
	Attach Current & Pending Support (Support_LastName.pdf) for each senior/key person to the appropriate field.	
Research & Related Budget	Complete form as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.	
Project/Performance Site Location(s) Form	Complete form as instructed.	
R & R Subaward Budget Attachment(s) Form	Complete form as instructed.	



REPLY TO
ATTENTION OF

MCHE-MDI

DEPARTMENT OF THE ARMY
BROOKE ARMY MEDICAL CENTER
3851 ROGER BROOKE DRIVE
FORT SAM HOUSTON TX 78234-6200

23 April 2010

MEMORANDUM FOR RECORD

SUBJECT: Infectious Disease Threats to the US Military Prioritization Panel Results

1. A panel was hosted by the Directorate of Combat and Doctrine Development (DCDD) and the Military Infectious Diseases Research Program (MIDRP), US Army Medical Research and Materiel Command (MRMC), under the umbrella of the Medical Force Protection Integrated Capabilities Development Team (ICDT) Charter to prioritize the current infectious disease threats to the US Military (Appendix A).
2. Panel objectives were to identify and operationally prioritize the infectious disease threats to US Forces to assist in the determination of capability requirements.
3. References included "Initial Capabilities Document (ICD) for Infectious Disease Countermeasures (IDCM)," 2006, and "Infectious Diseases Investment Decision Evaluation Algorithm: A Quantitative Algorithm for Prioritization of Naturally Occurring Infectious Disease Threats to the U.S. Military," *Military Medicine* 2008;173:174-181.
4. The panel was comprised of infectious disease experts, combatant and other major Command representatives (Appendix B and C); meeting on Fort Sam Houston, TX, 19-20 April 2010. On the first day of the meeting presentations were made by representatives from NCMI, AFHSC, OASH(HA), MIDRP, DCDD, AFRICOM, NORTHCOM, PACOM, SOCOM, and TRANSCOM. Following these presentations, deliberations to produce a new prioritized list of infectious disease threats to the US Military were conducted on the afternoon of the 19th and morning of the 20th. Decision-making computer support (ThinkTank) was employed to allow anonymous voting during these sessions. The final prioritized list of infectious disease threats to the US Military (Appendix A) was unanimously approved by the voting members of the panel (Appendix B) at the end of these deliberations.
5. Point of contact for this memorandum is COL Duane Hospenthal at (210) 916-3847, or duane.hospenthal@us.army.mil.

DUANE R. HOSPENTHAL, MD, PHD
COL, MC
Chief, Infectious Disease Service, and
Infectious Disease Consultant to the
US Army Surgeon General



Atch 1

Appendix A
Prioritization of Infectious Disease Threats to the US Military

1. Malaria
2. Dengue
3. Diarrhea, bacterial
4. Multidrug-resistant (MDR) wound pathogens
5. Leishmaniasis
6. Q fever (<i>Coxiella burnetii</i>)
7. Norovirus and other viral diarrhea
8. Influenza
9. Adenovirus
10. Leptospirosis
11. Diarrhea, protozoal
12. Tuberculosis (TB)
13. Crimean-Congo hemorrhagic fever
14. Human immunodeficiency virus (HIV/AIDS)
15. Hemorrhagic fever with renal syndrome (HFRS)
16. Chikungunya
17. Meningococcal meningitis
18. Plague
19. Rickettsioses
20. Viral encephalitides
21. Hepatitis E
22. Lassa fever and other arenaviruses
23. Tick-borne encephalitis
24. Rift Valley fever
25. Hepatitis C
26. Brucellosis
27. Other arboviral illnesses
28. Typhoid fever
29. Cholera
30. Schistosomiasis
31. Tularemia
32. Trypanosomiasis
33. Ebola/Marburg hemorrhagic fever
34. Chagas' disease
35. Yellow fever
36. Lyme
37. Bartonellosis (Oroya fever)
38. Soil-transmitted helminths